By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Social Media Guidance: Hangout on Air
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > eHealth > Social Media > FDA Social Media Guidance: Hangout on Air
BusinessPolicy & LawSocial Media

FDA Social Media Guidance: Hangout on Air

David Harlow
David Harlow
Share
4 Min Read
SHARE

Last month, the FDA released draft guidance on social media and internet platforms with character space limitations and a separate draft guidance for correcting misinformation posted online. Some of us had been waiting for these guidelines for five years or more.

I discussed these guidance documents with Kathi Browne in a Google+ Hangout on Air:

Last month, the FDA released draft guidance on social media and internet platforms with character space limitations and a separate draft guidance for correcting misinformation posted online. Some of us had been waiting for these guidelines for five years or more.

I discussed these guidance documents with Kathi Browne in a Google+ Hangout on Air:

More Read

Social Media Marketing, Medical Practice Marketing, Online Marketing
Social Media and Medical Practices: What Works and What Doesn’t
Kratom – a Solution for Opioid Addiction?
So, You Want to Go to Medical School? We Have Some Budget Tips For You
HealthCare Marketing: Choosing the Right Healthcare Advertising Channel
Temporary Health Plans With Low Benefits Continue to Grow

Key takeaways:

  • The draft guidance makes use of Twitter and platforms like Google Ads extremely unattractive, because the vast majority of the “real estate” must be given over to brand and generic names, indications for use, benefits, risks, and a link to fuller information about risks.
  • The FDA addressed itself to short-form communication without considering the way in which it is used most effectively – not as a canvas for ads, but as a forum for conversation.
  • Unbranded tweetchats, Facebook pages, and the like were OK before the draft guidance was issued, and they still are.
  • The correction of misinformation guidance lowers the regulatory bar for corrections (vs. marketing messages that must meet higher standards and may be subject to pre-review).
  • The misinformation guidance does not require a drug or device manufacturer to address all misinformation online about its products. Corrections must be focused responses to what others put out there on line, and should link to fuller information where appropriate, but corrections should not include or link to promotional material.
  • The misinformation guidance delineates an area of opportunity for drug and device manufacturers.

Please take the time to watch the whole video if you are interested in this subject, and let’s continue the conversation in the comments section or in another online forum.

Interestingly, the FDA has already taken action based on its subregulatory draft interpretations of the statutes and regulations that are applicable in this arena. Specifically, it has sanctioned two companies – one, for branded use of Google Ad Words that did not comply with relevant requirements (the drug in question was being promoted as a cure for a condition, when in fact it has been approved only as a treatment for symptoms; the ad omitted risk information; the established name for the drug was not used; and the ad was not submitted to the FDA), and the other, for website, Twitter and Facebook claims about products sold over the counter that have never been subject to FDA review; and liking Facebook posts endorsing one or more of its products — which the FDA views as “misbranded” “new drugs” since the seller is making claims as to efficacy in treating certain conditions even though they had never been approved by the FDA.

The FDA is accepting comments on the draft guidance through mid-September.

TAGGED:FDA
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025
Guide To Pursuing a Career in Nursing as a Foreigner in the USA
Collaboration Is the Prescription for Better Patient Care
Health
October 20, 2025
Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025

You Might also Like

siipc14
BusinesseHealthHealth ReformMobile HealthPublic Health

Keeping Patients in the Dark

July 6, 2014
Health carePublic Health

The Link Between Sustainability And Health

August 9, 2020
healthcare value
BusinessFinance

Defining Healthcare Value

June 14, 2014
marketing to millennials
Social MediaTechnology

Medical Marketing to Millennials: Convenience is the New Currency

June 2, 2016
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?